Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 8/20 | 0.47 |
| ▸ | CFD | P00746 | 7/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855020 | 0.84 | CFD (0.43) | SLC22A12CFDHCAR3 | |
| SCHEMBL20487924 | 0.84 | CFD (0.43) | SLC22A12CFDHCAR3 | |
| SCHEMBL25926111 | 0.82 | CFD (0.39) | SLC22A12CFD | |
| SCHEMBL25940602 | 0.81 | TDP1 (0.48) | CFDMAPTKMT2A | |
| SCHEMBL12480012 | 0.79 | CFD (0.48) | CFD | |
| SCHEMBL25940616 | 0.76 | ALDH1A1 (0.38) | CFDMAPT | |
| SCHEMBL18554320 | 0.76 | ESR1 (0.42) | CFD | |
| SCHEMBL19208536 | 0.76 | ELANE (0.41) | SLC22A12CFDMAPTKMT2A | |
| SCHEMBL29781683 | 0.76 | ELANE (0.41) | SLC22A12CFDMAPTKMT2A | |
| SCHEMBL25925430 | 0.76 | CFD (0.49) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | SLC22A12 2843/4885CFD 1/4885HCAR3 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.